New diabetes pill shows promise in early trial

NCT ID NCT01022112

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tested an experimental oral drug called TA-7284 in 383 adults with type 2 diabetes. The drug works by helping the kidneys remove extra sugar through urine. Researchers compared four different doses of TA-7284 against a placebo to see how well it lowers blood sugar and whether it is safe. The study is already completed, and results will help decide if larger trials are warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TA-7284 (an SGLT2 inhibitor drug taken by mouth)
What this could lead to: If successful, this could lead to a new oral medication to help people with type 2 diabetes better control their blood sugar levels.
What could go wrong: This is an early Phase 2 dose-ranging study, so results may not confirm effectiveness or safety. The drug may cause side effects or fail to outperform placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

Research site

Chugoku, Japan
Research site

Kanto, Japan
Research site

Kinki, Japan
Research site

Kyushu, Japan
Research site

Shikoku, Japan
Research site

Tōhoku, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.